We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

15 hedge funds and large institutions have $958K invested in Oruka Therapeutics in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% less ownership

Funds ownership: 0.08% → 0.06% (-0.03%)

6% less funds holding

Funds holding: 16 → 15 (-1)

23% less capital invested

Capital invested by funds: $1.24M → $958K (-$283K)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$26.4K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$25.9K
3
UBS Group
UBS Group
Switzerland
+$2.82K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.11K
5
Morgan Stanley
Morgan Stanley
New York
+$939

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$175K
2
RA
Royce & Associates
New York
-$163K
3
Renaissance Technologies
Renaissance Technologies
New York
-$62.1K
4
VF
Virtu Financial
New York
-$18.4K
5
TSS
Two Sigma Securities
New York
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tekla Capital Management
Massachusetts
$451K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$233K -$62.1K -529 -21%
Acadian Asset Management
3
Acadian Asset Management
Massachusetts
$56K – – –
ACP
4
Aveo Capital Partners
Colorado
$52K – – –
PAM
5
Panagora Asset Management
Massachusetts
$49K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$27K +$26.4K +225 New
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
$26K +$25.9K +221 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$22K +$2.11K +18 +11%
VF
9
Virtu Financial
New York
$19K -$18.4K -157 -50%
CS
10
Credit Suisse
Switzerland
$11K – – –
Northern Trust
11
Northern Trust
Illinois
$8K – – –
UBS Group
12
UBS Group
Switzerland
$3K +$2.82K +24 New
Morgan Stanley
13
Morgan Stanley
New York
$1K +$939 +8 +800%
Deutsche Bank
14
Deutsche Bank
Germany
– -$175K -1,630 Closed
RA
15
Royce & Associates
New York
– -$163K -1,510 Closed
TSS
16
Two Sigma Securities
New York
– -$16K -150 Closed
Millennium Management
17
Millennium Management
New York
– -$6K -52 Closed
Bank of America
18
Bank of America
North Carolina
– -$117 -1 -25%

ORKA Hedge Fund Activity: Q2 2018 in Review

15 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2018, worth a combined $958K — down 23% from $1.24M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ORKA and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $26.4K. The largest seller was Deutsche Bank, exiting entirely with an estimated $175K sold.

  • 15 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2018, down from 16 in Q1 2018.
  • Funds reported $958K of Oruka Therapeutics stock for Q2 2018, down 23% quarter-over-quarter.
  • 3 funds opened new Oruka Therapeutics positions in Q2 2018 and 4 closed out, a net change of -1 holder.
  • The largest Oruka Therapeutics buyer in Q2 2018 was Geode Capital Management, an estimated $26.4K added.
  • The largest Oruka Therapeutics seller in Q2 2018 was Deutsche Bank, an estimated $175K sold.

Based on aggregated 13F filings for Q2 2018.